KCL-286 Targets DNA Damage and Inflammation in Preclinical Alzheimer’s Study

The most notable feature of KCL-286 is its reach across several processes linked to Alzheimer’s disease. In a mouse model, the experimental drug helped repair DNA breaks and reduced brain inflammation, two changes researchers say can arise early in the disease. The results point to a treatment strategy that extends beyond amyloid-beta and tau, the proteins at the center of much Alzheimer’s drug development.

That breadth makes KCL-286 an interesting candidate, but the evidence is still preclinical. The study does not establish that the drug slows Alzheimer’s or improves outcomes in people. Its earlier completion of Phase 1 human safety and tolerability trials gives researchers a starting point for further development; it does not answer whether the drug works against Alzheimer’s in humans.

A wider set of targets

Alzheimer’s involves multiple changes in the brain. Amyloid-beta can accumulate in deposits between nerve cells, while abnormal tau forms tangles inside them. These features are associated with disrupted brain function and the progressive loss of neurons, which carry information through the brain.

Drugs designed to remove amyloid-beta have shown modest but measurable clinical benefits, according to the source material. But focusing on that protein does not address every biological process involved in the disease. Researchers are therefore examining other possible contributors, including DNA damage and inflammation.

KCL-286 was tested in mice with Alzheimer’s-like disease. The researchers reported that it promoted repair of DNA breaks and reduced inflammation. The combination matters because it suggests the drug can affect more than one disease-relevant process in the model, rather than acting on a single hallmark such as amyloid-beta or tau.

Dr. Maria Goncalves, who project-managed the drug development, said the findings show that KCL-286 targets DNA damage and reduces inflammation, both of which occur early in Alzheimer’s progression. She described this as a potential disease-modifying approach rather than one aimed only at symptoms. That remains a research possibility, not a demonstrated effect in patients.

Why the retinoic acid pathway matters

KCL-286 is an orally available small molecule that activates a specific protein in the retinoic acid pathway, a system linked to how the body processes and uses vitamin A. Retinoic acid, a substance derived from vitamin A, helps regulate genes involved in cellular development and other biological functions, including nervous system activity.

The pathway drew the team’s attention in part because earlier research associated disruptions in it with amyloid-beta deposits in rat brains. Those deposits resemble a major feature of Alzheimer’s pathology. That connection gave researchers a reason to investigate whether influencing the pathway could affect changes linked to the disease.

The drug also had a relevant track record in research on neuropathic pain, which results from damage or dysfunction in the nervous system. Earlier work found that KCL-286 could promote repair of DNA double-strand breaks. The team then asked whether the same mechanism might be useful against DNA damage associated with Alzheimer’s.

A double-strand break occurs when both strands of a DNA molecule are severed. Because DNA carries the instructions cells need to function, this kind of damage can interfere with normal cellular activity and threaten cell survival if it is not repaired. Professor Jonathan Corcoran, a neuroscience professor at King’s College London’s Institute of Psychiatry, Psychology & Neuroscience, compared such a break to “a rope snapping completely in two, rather than just fraying at the edges.”

From spinal cord injury research to Alzheimer’s

The drug’s development began in a different area: spinal cord injury. Previous work by the same King’s College London team identified molecular pathways shared by acute spinal cord injury and Alzheimer’s disease. The overlap led the researchers to consider whether a candidate developed to address nervous system damage might also affect Alzheimer’s-related changes in neurons.

The new mouse findings support that line of inquiry. They suggest KCL-286 can influence several cellular pathways relevant to Alzheimer’s, including DNA repair and inflammation. The results don’t establish how much each pathway contributes to any benefit, or whether the effects seen in mice will translate to people.

There is a practical development point, too. KCL-286 can be taken by mouth, and it has already completed Phase 1 human safety and tolerability trials in its earlier development. Professor Corcoran called it a “first-in-class, orally bioavailable small molecule” and said its prior testing could shorten the traditional timeline for developing a new drug. Phase 1 safety testing, however, is not evidence of effectiveness against Alzheimer’s.

The next question is whether the effects translate

The central question now is whether further studies can show that KCL-286 safely changes the course of Alzheimer’s in people. The current results come from an animal model, so additional research and human clinical trials are needed before researchers can determine whether the drug slows progression or improves patient outcomes.

Natasha Hill, one of the paper’s first authors, said effective Alzheimer’s treatment will require addressing multiple aspects of the disease. In her view, KCL-286’s ability to target several disease-relevant cellular pathways, including some initiated early in the disease course, is a reason to pursue the approach.

For now, the study’s value lies in the direction it tests: combining attention to DNA repair and inflammation with the established focus on Alzheimer’s hallmark proteins. KCL-286’s prior safety testing may make continued development more direct, but the decisive evidence will have to come from studies that test its effects in people with Alzheimer’s.

Materials provided by King's College London. Note: Content may be edited for style and length.

Scientists Finally Identify Mysterious Creature Nearly 90 Years After It Was First Found

Scientists Say This Medication Could Be the Next “Wonder Drug”

A Hidden DNA Mechanism Could Explain How 20% of Human Cancers Develop

A Nutrient Found in Red Meat Could Make Dangerous Inflammation Even Worse

Stay informed with ScienceDaily's free email newsletter, updated daily and weekly. Or view our many newsfeeds in your RSS reader:

Keep up to date with the latest news from ScienceDaily via social networks:

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?